14th InSysBio’s Annual Internal Scientific Meeting

February 22, 2024

InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, held its 14th Annual Internal Scientific Meeting on February 11-13, 2024. The Meeting was organized for the first time after the pandemic and InSysBio’s Headquarters relocation to Cyprus.

InSysBio’s teams presented the results of 2023 performance and discussed plans and ideas for the future development. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, opened the Meeting by the overview of InSysBio’s twenty years of operation. During this period InSysBio performed a diverse range of QSP modeling projects in collaboration with pharmaceutical giants. Moreover, InSysBio developed its own fully-fledged QSP infrastructure that includes QSP databases (CYTOCON DB, fIVE DB), softs (Heta) and tools (IRT). All of them were significantly enhanced throughout the year and further update is underway. In frames of QSP models and platforms development the company experienced in a variety of therapeutic areas and currently mainly focuses on oncology, immunology, immuno-oncology, rare diseases and neurodegenerative diseases. In 2023 InSysBio participated in four conferences, namely, PAGE 2023, World Bispecific Summit 2023, SITC 2023 and ACoP14.

The Meeting was closed up by a heated discussion of AI and ML in QSP modeling. Besides, the perspective outlook shows that the company has intention towards constant growth. This year InSysBio is going to present its results at ASCPT 2024, PAGE 2024, ACoP15.

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com